The effect of somatostatin analogue SMS 201-995 on serotonin levels in the medium of primary carcinoid cell cultures.

Carcinoid cell cultures were established from primary tumours and liver and mesenteric metastases. The cells continued to produce serotonin for up to 6 months. Cells from different tumours showed different properties. In most wells carcinoid cells grew on a layer of fibroblasts. The tendency to co-culture seemed to be less marked in cells from liver biopsy specimens. The amount of serotonin decreased to 63% 300 min after addition of the somatostatin analogue SMS 201-995 (SMS) to the culture, compared with controls (p < 0.05; n = 10). This decrease was observed up until 12 days, when SMS was added at each change of medium (p < 0.005; n = 8). In the first 10 min, however, SMS induced an increase in serotonin concentration (p < 0.005; n = 11). This effect may be related to other, immediate stimulatory effects of SMS seen in other cell lines originating from neural ridge-derived tissue. We believe it is important to elucidate the properties of individual tumours, as choice of therapy may vary between patients with the same diagnosis. We have described a method to obtain such information within a couple of days, before a definite treatment is selected.

[1]  B. Haber,et al.  The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor. , 1990, Surgery.

[2]  D. Banville,et al.  Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins. , 1990, Metabolism: clinical and experimental.

[3]  E. Krenning,et al.  Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs. , 1990, Metabolism: clinical and experimental.

[4]  A. Harris.  Future medical prospects for Sandostatin. , 1990, Metabolism: Clinical and Experimental.

[5]  J. W. Tanner,et al.  Modulation of growth hormone (GH) secretion and GH mRNA levels by GH-releasing factor, somatostatin and secretagogues in cultured bovine adenohypophysial cells. , 1990, The Journal of endocrinology.

[6]  R. McKay,et al.  The use of cell lines in neurobiology , 1990, Trends in Neurosciences.

[7]  A. Schally,et al.  Evaluation of receptors for somatostatin in various tumors using different analogs. , 1990, The Journal of clinical endocrinology and metabolism.

[8]  J. Rastad,et al.  Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. , 1990, Cancer research.

[9]  D. Allison,et al.  Therapy for symptoms in the carcinoid syndrome. , 1989, The Quarterly journal of medicine.

[10]  A. Dahlström,et al.  Presence of nerve growth factor‐like immunoreactivity in carcinoid tumour cells and induction of a neuronal phenotype in long‐term culture , 1989, International journal of cancer.

[11]  E. Theodorsson,et al.  The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome. , 1989, The Journal of clinical endocrinology and metabolism.

[12]  J. Rask-Madsen,et al.  Involvement of 5-hydroxytryptamine, prostaglandin E2, and cyclic adenosine monophosphate in cholera toxin-induced fluid secretion in the small intestine of the rat in vivo. , 1989, Gastroenterology.

[13]  V. Go,et al.  Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut , 1989 .

[14]  A. Dahlström,et al.  Carcinoid tumour cells in long‐term culture: Release of serotonin but not of tachykinins on stimulation with adrenoceptor agonists , 1988, International journal of cancer.

[15]  K. Gautvik,et al.  Somatostatin inhibits prolactin secretion by multiple mechanisms involving a site of action distal to increased cyclic adenosine 3',5'-monophosphate and elevated cytosolic Ca2+ in rat lactotrophs. , 1988, Acta physiologica Scandinavica.

[16]  A. Dahlström,et al.  Use of a somatostatin analogue in association with surgery and hepatic arterial embolisation in the treatment of the carcinoid syndrome. , 1987, British Journal of Cancer.

[17]  C. Wollheim,et al.  Oscillations of cytosolic Ca2+ in pituitary cells due to action potentials , 1987, Nature.

[18]  H. Tamir,et al.  Induction of a neural phenotype in a serotonergic endocrine cell derived from the neural crest , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[19]  L. Kvols,et al.  Treatment of the Malignant Carcinoid Syndrome , 1987 .

[20]  L. Kvols,et al.  Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. , 1986, The New England journal of medicine.

[21]  E Theodorsson-Norheim,et al.  Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush. , 1986, The Journal of clinical endocrinology and metabolism.

[22]  T. Bjøro,et al.  The phorbol ester TPA induces hormone release and electrical activity in clonal rat pituitary cells. , 1986, Acta physiologica Scandinavica.

[23]  J. Reubi.  A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. , 1985, Acta endocrinologica.

[24]  A. Schally,et al.  Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Modigliani,et al.  Serotonin‐secreting and insulin‐secreting ileal carcinoid tumor and the use of in vitro culture of tumoral cells , 1984, Cancer.

[26]  C. Wollheim,et al.  Somatostatin lowers the cytosolic free Ca2+ concentration in clonal rat pituitary cells (GH3 cells). , 1984, Cell calcium.

[27]  A. Schally,et al.  Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Marbach,et al.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. , 1982, Life sciences.

[29]  J. Launay,et al.  Serotonin and histamine production by human carcinoid cells in culture. , 1982, Cancer research.

[30]  M. Stachura.  Potassium modification of the somatostatin effect on stimulated rat growth hormone release. , 1981, Endocrinology.

[31]  J. Kraicer,et al.  Release of growth hormone from purified somatotrophs: use of high K+ and the ionophore A23187 to elucidate interrelations among Ca++, adenosine 3',5'-monophosphate, and somatostatin. , 1981, Endocrinology.

[32]  A. Schonbrunn,et al.  Inhibition of adrenocorticotropin secretion by somatostatin in pituitary cells in culture. , 1981, Endocrinology.

[33]  C. L. Blank,et al.  Liquid-chromatographic determination of serotonin in serum and plasma. , 1978, Clinical chemistry.

[34]  N. Ling,et al.  Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone , 1973, Science.

[35]  M. Spatz.  PATHOGENETIC STUDIES OF EXPERIMENTALLY INDUCED HEART LESIONS AND THEIR RELATION TO THE CARCINOID SYNDROME. , 1964, Laboratory investigation; a journal of technical methods and pathology.